Targeting uPA-uPAR interaction to improve intestinal epithelial barrier integrity in inflammatory bowel disease - eBioMedicine

TRIM40 is a pathogenic driver of inflammatory bowel disease subverting intestinal barrier integrity. - Abstract - Europe PMC

Urokinase-type plasminogen activator blockade ameliorates experimental colitis in mice

Integrative analysis reveals marker genes for intestinal mucosa barrier repairing in clinical patients. - Abstract - Europe PMC

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants - eBioMedicine

Frontiers Emerging strategy towards mucosal healing in inflammatory bowel disease: what the future holds?

uPAR, beyond regulating physiological functions, has orchestrated roles in cancer (Review)

Urokinase-type plasminogen activator blockade ameliorates experimental colitis in mice

TRIM40 is a pathogenic driver of inflammatory bowel disease subverting intestinal barrier integrity. - Abstract - Europe PMC

Urokinase-type plasminogen activator blockade ameliorates experimental colitis in mice

Pathologically catalyzed physical coating restores the intestinal barrier for inflammatory bowel disease therapy, Journal of Nanobiotechnology

Frontiers Enhancing intestinal barrier efficiency: A novel metabolic diseases therapy

Evaluation of Intestinal Epithelial Barrier Function in Inflammatory Bowel Diseases Using Murine Intestinal Organoids. - Abstract - Europe PMC

Full article: Beta-carotene regulates the biological activity of EGF in IEC6 cells by alleviating the inflammatory process

uPAR, beyond regulating physiological functions, has orchestrated roles in cancer (Review)

Mend Your Fences: The Epithelial Barrier and its Relationship With Mucosal Immunity in Inflammatory Bowel Disease - ScienceDirect